Efficacy and safety of daridorexant in Chinese patients with insomnia disorder: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial
SLEEPJ · 11.12.2025 · 48 (12)
DOI: 10.1093/sleep/zsaf170 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift SLEEPJ, online erschienen am 25.06.2025. Verfasst von Zhaoyang Huang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Pyrrolidines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Jiangsu Simcere Pharmaceutical Co., Ltd..
Themen: Schlaf
Abstract (Originalsprache)
Study Objectives To evaluate the efficacy and safety of daridorexant in Chinese patients with insomnia disorder.
Methods
This was a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III clinical trial in China. Adults aged 18–75 years meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for insomnia disorder, with a baseline Insomnia Severity Index (ISI) more than equal to 15, were randomly assigned in a 1:1 ratio to receive daridorexant 50 mg or placebo once every evening for 1 month. The primary endpoint was the change from baseline to month 1 in wake time after sleep onset (WASO) assessed by polysomnography (PSG). The secondary endpoints included the change from baseline to month 1 in self-reported total sleep time (sTST) and in latency to persistent sleep (LPS). In addition to the standardized collection of adverse events (AEs), safety data specific to insomnia treatment were assessed as follows: withdrawal symptoms, rebound insomnia, and next-day residual effects.
Results
Two hundred and six participants were enrolled and evenly randomized to each group. Compared with the placebo group, the daridorexant group showed a significant reduction in WASO (−15.4 min, p = .0009), a significant increase in sTST (16.8 min, p = .021) and a significant reduction in LPS (geometric mean ratio to placebo 0.7, p = .001) from baseline to month 1. The proportion of participants reporting AEs during double-blind treatment was generally comparable between two groups (21.6 vs. 18.4 percent), with no notable safety signals observed. No withdrawal symptoms, rebound insomnia, and next-day residual effects were observed.
Conclusions
Daridorexant 50 mg significantly improved both objective and self-reported sleep outcomes in Chinese patients with insomnia disorder, with a favorable safety profile. Clinical Trial A Study of Daridorexant in Chinese Patients With Insomnia Disorder, https://clinicaltrials.gov/study/NCT06010693, with the number NCT06010693. Statement of Significance Daridorexant has been evaluated and approved for the treatment of insomnia in many countries worldwide, but there is no data of daridorexant in Chinese populations. This study is the first randomized controlled phase III study of daridorexant in Chinese. It verified the efficacy and safety of daridorexant in Chinese people for the first time and fully explained the characteristics of daridorexant in Chinese patients with insomnia. This study provides a basis for the approval of daridorexant for clinical use in China, as well as reference data for clinicians to use the drug in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
- Beijing Key Laboratory of Neuromodulation, Capital Medical University, Beijing, China.
- Department of Sleep Medicine, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Psychiatry, Sleep Medicine Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Neurology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.
- Department of Neurology, Chengdu Second People's Hospital, Chengdu, China.
ORCID-Profile: Jingxu Chen, Yuping Wang
Förderung
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Zitieren
APA
Huang, Z., Wang, H., Zhang, B., Li, C., Wang, J., Xu, L., Xu, Q., Chen, J., Xiao, L., Wang, Z., Wang, B., Jiang, Y., Liu, Y., Yuan, C., Ma, Q., Wu, J., Liu, X., Huang, Y., Cui, H., …, & Wang, Y. (2025). Efficacy and safety of daridorexant in Chinese patients with insomnia disorder: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial. SLEEPJ, 48(12). https://doi.org/10.1093/sleep/zsaf170
Vancouver
Huang Z, Wang H, Zhang B, Li C, Wang J, Xu L, et al. Efficacy and safety of daridorexant in Chinese patients with insomnia disorder: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial. SLEEPJ. 2025;48(12). doi:10.1093/sleep/zsaf170
BibTeX
@article{Huang2025,
author = {Huang, Zhaoyang and Wang, Hanqiao and Zhang, Bin and Li, Chenyu and Wang, Jian and Xu, Lijun and Xu, Qiaorong and Chen, Jingxu and Xiao, Li and Wang, Zan and Wang, Bei and Jiang, Yan and Liu, Yunlin and Yuan, Chengmei and Ma, Qinying and Wu, Juncang and Liu, Xin and Huang, Yuansheng and Cui, Hao and Wang, Feng and Wang, Yuping},
title = {Efficacy and safety of daridorexant in Chinese patients with insomnia disorder: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial},
journal = {SLEEPJ},
year = {2025},
volume = {48},
number = {12},
doi = {10.1093/sleep/zsaf170}
}
EUVIMED